Evotec SE ADR(EVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:04 PM ET (Korea 10/31 06:04)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.65 | Insider Own | 5.17% | Shs Outstand | 355.2M | Perf Week | 2% |
| Market Cap | 0.54B | Forward P/E | - | EPS next Y | 72.7% | Insider Trans | - | Shs Float | 336.8M | Perf Month | -6.99% |
| Enterprise Value | 0.56B | PEG | - | EPS next Q | -0.18 | Inst Own | 0.96% | Short Float | 0.02% | Perf Quarter | -21.13% |
| Income | -0.23B | P/S | 0.65 | EPS this Y | -131.89% | Inst Trans | -3.73% | Short Ratio | 0.71 | Perf Half Y | -50.49% |
| Sales | 0.84B | P/B | 0.71 | EPS next 5Y | - | ROA | -11.74% | Short Interest | 0.08M | Perf YTD | -50.32% |
| Book/sh | 2.14 | P/C | 1.02 | EPS past 3/5Y | 14.3% - | ROE | -26.25% | 52W High | -62.86% ($4.12) | Perf Year | -62.32% |
| Cash/sh | 1.5 | P/FCF | - | Sales past 3/5Y | 4.05% 9.27% | ROIC | -18.65% | 52W Low | 15.04% ($1.33) | Perf 3Y | -81.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -35.64% | Gross Margin | 10.47% | Volatility(W/M) | 2.95% 3.63% | Perf 5Y | -93.63% |
| Dividend TTM | - | EV/Sales | 0.66 | Sales Y/Y TTM | -0.86% | Oper. Margin | -18.62% | ATR (14) | 0.06 | Perf 10Y | -45.21% |
| Dividend Ex-Date | 2019/1/11 | Quick Ratio | 2.21 | EPS Q/Q | -10.02% | Profit Margin | -27.53% | RSI (14) | 47.22 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.33 | Sales Q/Q | -14.05% | SMA20 | 1.17% ($1.51) | Beta | 2.01 | Target Price | $2.32 |
| Payout | - | Debt/Eq | 0.71 | Earnings | 2026/8/13 | SMA50 | -7.16% ($1.65) | Rel Volume | 0.68 | Prev Close | $1.58 |
| Employees | 4553 | LT Debt/Eq | 0.62 | EPS/Sales Surpr. | -275.25% 0.91% | SMA200 | -39.3% ($2.52) | Avg Volume(3M) | 0.11M | Price | $1.53 |
| IPO | 2004/2/5 | Option/Short | No/Yes | Trades | 162 | Volume | 73,257 | Change | -3.16% |
🧬 Evotec (EVO) is a global drug discovery and development partner based in Germany. It is an integrated contract research organization (CRO) that provides end-to-end services—from drug discovery through preclinical development—on behalf of pharmaceutical and biotech clients, and it also operates a contract manufacturing platform for biopharmaceuticals. The company covers a wide range of modalities, from small-molecule compounds to biotherapeutic treatments.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
EVO has a sound balance sheet but weak earning power
Of every $100 in sales, $18.62 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -131.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $65. Peers typically go for $158.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #37 of 83 in the industry
Based on market cap of $543M.
FAQ
What kind of company is EVO?
EVO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of EVO?
The market cap of EVO is approximately $543M, ranking 3,067 within its sector.
What is the 52-week high and low for EVO?
EVO has recorded a 52-week high of $4.12 and a low of $1.33.
